Daniel Sommermeyer

Daniel Sommermeyer serves as the Vice President of Cell Therapy Innovate Oncology at Evotec since November 2021. Prior to this role, Daniel held the position of Director for the TCR Discovery Platform at Medigene AG from March 2016 to October 2021. Daniel's academic career includes positions as a Research Scientist and Postdoctoral Research Fellow at Fred Hutchinson Cancer Research Center from March 2012 to February 2016, and as a Postdoctoral Research Fellow at Max Delbrück Center for Molecular Medicine from January 2010 to February 2012. Daniel earned a PhD in Immunology from Humboldt-Universität zu Berlin (2004-2010), a Diplom in Biochemistry from Friedrich Schiller University Jena (2001-2004), and a Vordiplom in Biochemistry from the University of Bayreuth (1999-2001).